Her main research concerns Breast cancer, Internal medicine, Oncology, Genome-wide association study and Genetics. The study incorporates disciplines such as Single-nucleotide polymorphism and Genotype in addition to Breast cancer. Rita K. Schmutzler usually deals with Internal medicine and limits it to topics linked to Olaparib and Iniparib, PARP inhibitor and Tolerability.
Her Oncology research incorporates themes from Gene mutation, Gynecology, Ovarian cancer, Prospective cohort study and Prostate cancer. Rita K. Schmutzler combines subjects such as Mendelian randomization, Disease, Genetic predisposition, Bioinformatics and Genetic association with her study of Genome-wide association study. Her Genotyping, Locus, Genetic variation and Missense mutation study in the realm of Genetics connects with subjects such as UBA1.
Breast cancer, Internal medicine, Oncology, Genetics and Cancer are her primary areas of study. She has researched Breast cancer in several fields, including Cancer research, Genome-wide association study, Genotype, Single-nucleotide polymorphism and Ovarian cancer. As a member of one scientific family, Rita K. Schmutzler mostly works in the field of Ovarian cancer, focusing on Genetic testing and, on occasion, Genetic counseling.
Her Internal medicine research incorporates elements of Germline mutation and Gynecology. As a part of the same scientific family, Rita K. Schmutzler mostly works in the field of Oncology, focusing on Hazard ratio and, on occasion, Proportional hazards model. Her Cancer research includes themes of Disease and Pathology.
Breast cancer, Internal medicine, Oncology, Ovarian cancer and Germline mutation are her primary areas of study. Her Breast cancer research is under the purview of Cancer. Her Internal medicine study frequently draws connections to other fields, such as Mutation.
Her research in Oncology tackles topics such as Hazard ratio which are related to areas like Single-nucleotide polymorphism, Proportional hazards model, Cohort study and Genome-wide association study. The various areas that Rita K. Schmutzler examines in her Germline mutation study include Prostate, Therapy response and Early breast cancer. Her Cancer research research includes elements of EZH2, Fanconi anemia and Olaparib.
Rita K. Schmutzler mainly focuses on Breast cancer, Internal medicine, Oncology, Prospective cohort study and Germline mutation. Her study in Breast cancer focuses on Estrogen receptor in particular. Her study looks at the relationship between Estrogen receptor and fields such as Genome-wide association study, as well as how they intersect with chemical problems.
She interconnects Single-nucleotide polymorphism and PALB2 in the investigation of issues within Internal medicine. Her research integrates issues of Odds ratio, Cancer, Prostate cancer, Genetic counseling and Genetic testing in her study of Oncology. Her biological study spans a wide range of topics, including Incidence, Cohort study and Mutation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek.
The Lancet (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
A Tutt;M Robson;J E Garber;S M Domchek.
The Lancet (2010)
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B. Kuchenbaecker;Karoline B. Kuchenbaecker;John L. Hopper;Daniel R. Barnes;Kelly-Anne Phillips.
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman;Ronnie Shapira-Frommer;Rita K. Schmutzler;M. William Audeh.
Journal of Clinical Oncology (2015)
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Kyriaki Michailidou;Per Hall;Anna Gonzalez-Neira;Maya Ghoussaini.
Nature Genetics (2013)
RAD51B in Familial Breast Cancer
Liisa M. Pelttari;Sofia Khan;Mikko Vuorela;Johanna I. Kiiski.
PLOS ONE (2016)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley.
Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores
Bjarni J. Vilhjálmsson;Jian Yang;Hilary K. Finucane;Alexander Gusev.
American Journal of Human Genetics (2015)
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
Alfons Meindl;Heide Hellebrand;Constanze Wiek;Verena Erven.
Nature Genetics (2010)
Breast MR Imaging Screening in 192 Women Proved or Suspected to Be Carriers of a Breast Cancer Susceptibility Gene: Preliminary Results
Christiane Katharina Kuhl;Rita K. Schmutzler;Claudia Christiane Leutner;Andrea Kempe.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: